COVID-19 Vaccine Hesitancy and Dental Faculty Staff Members in Egypt

August 16, 2021 updated by: Mariam Ayman Amin Sharaf

COVID-19 Vaccine Hesitancy and Perceptions Among Teaching and Assisting Staff at Faculty of Dentistry, Ain Shams University in Egypt: A Cross-Sectional Study.

Healthcare workers (HCWs) play a vital role in determining the success of vaccination programs. Patient acceptance and vaccination rely greatly on the utilization and attitude of HCWs towards the vaccine, their attitude also influences patients' adherence to vaccination schedules and their hesitancy. HCWs themselves can be hesitant about a certain vaccine and thus can transfer their negative attitudes to their patients, increasing vaccine hesitancy among the general population. Frontline HCWs are at an increased risk of exposure to COVID-19 due to their direct contact with their patients, working hours, psychological stress and job burnout, they also face stigma. Dental health professionals in particular are at an increased risk due to their occupational hazards that include continuous exposure to body fluids and aerosols, this increases their risk of contracting COVID-19. Therefore vaccinating healthcare workers will be beneficial, not only for themselves, but also for their households and patients.

Study Overview

Status

Enrolling by invitation

Detailed Description

To mitigate the rapid spread of COVID-19 and its massive impact on the economy worldwide, efforts have to be made to protect people against the disease, one of the most effective means was found to be vaccination. The range of technology in the development of COVID-19 vaccine is a striking feature where various approaches are being evaluated including, but not limited to: nucleic acid (DNA and RNA), recombinant protein, live-attenuated virus, inactivated virus and virus-like particles approaches. It is the responsibility of governments to ensure equity in the distribution and access to the novel vaccine. Authorized and currently available vaccines in Egypt include: 1) COVID-19 Vaccine AstraZeneca (AZD1222) which is an adenovirus vaccine manufactured in UK, 2) Sputnik V, a recombinant adenovirus vaccine manufactured in Russia and 3) BBIBP-CorV Sinopharm, which is an inactivated vaccine manufactured in China. The total number of vaccine doses administered in Egypt was reported to be 1,315 doses in March 2021.

However, vaccine availability is not enough to ensure large-scale immunization; success of vaccination programs depend greatly on the population's demand and acceptability of the vaccine. Governments should strive to understand determinants of vaccine acceptability and perception of people towards the vaccine. Although vaccination has largely contributed to decreasing the global burden of diseases and mortality, various factors can affect the acceptance of a new vaccine. "Vaccine hesitancy" has been declared by WHO as one of the ten global health threats worldwide, and has been defined as 'delay in acceptance or refusal of vaccination despite availability of vaccination services.' Causes of vaccine hesitancy include concerns about its safety, efficacy, personal beliefs, religious reasons, concerns about its rapid development as the rapid development of swine flu vaccine was previously associated with increased risk of Guillain-Barre syndrome, low benefits perceived and fear of side effects. Moreover, some people have concerns about the manufacturing process of the vaccine, as a defective polio vaccine lead to development of incident cases of polio and paralysis and death in earlier times.

In Egypt, healthcare workers are the first group to have access to COVID-19 vaccine and hence, act as a primary source of knowledge to the public about the vaccine, therefore it is crucial to estimate their level of perception and acceptability of the vaccine and determine factors affecting their acceptability. This will help inform stakeholders to make decisions regarding COVID-19 vaccination programs. To the best of our knowledge, this is the first study in Egypt targeting dental health professionals in particular, owing to their exclusive high exposure level to COVID-19 among healthcare workers

Study Type

Observational

Enrollment (Anticipated)

200

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Cairo, Egypt, 11311
        • AIN shams university

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Staff members of Faculty of Dentistry, Ain Shams University

Description

Inclusion Criteria:

  • Staff members at Faculty of Dentistry, Ain Shams University
  • Egyptians.

Exclusion Criteria:

  • Staff members who refuse to participate in the study.
  • Staff members currently living abroad. (As their perception about COVID-19 situation and risk in Egypt will not be accurate)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Staff members who accept/refuse vaccination against COVID-19
Time Frame: August 2021-October 2021
Percentage
August 2021-October 2021

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Perceived barriers and enablers of staff members to get vaccinated against COVID-19
Time Frame: August 2021-December 2021
August 2021-December 2021
Factors associated with acceptance of COVID-19 vaccination among staff members.
Time Frame: August 2021-December 2021
Demographics, previous COVID-19 experience, knowledge and attitude
August 2021-December 2021
Risk perception of COVID-19 among staff members.
Time Frame: August 2021-December 2021
August 2021-December 2021

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Amira Badran, PhD, AIN shams university
  • Principal Investigator: Mariam Sharaf, Msc, AIN shams university
  • Principal Investigator: Omar Taqa, Msc, AIN shams university
  • Study Chair: Haneen Zahran, Msc, AIN shams university

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 15, 2021

Primary Completion (Anticipated)

October 30, 2021

Study Completion (Anticipated)

December 30, 2021

Study Registration Dates

First Submitted

August 16, 2021

First Submitted That Met QC Criteria

August 16, 2021

First Posted (Actual)

August 17, 2021

Study Record Updates

Last Update Posted (Actual)

August 17, 2021

Last Update Submitted That Met QC Criteria

August 16, 2021

Last Verified

August 1, 2021

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Covid19

Subscribe